ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $771,189 | +15.9% | 8,850 | +21.4% | 0.04% | +20.0% |
| Q2 2023 | $665,322 | +8.6% | 7,288 | -5.1% | 0.04% | -2.8% |
| Q1 2023 | $612,394 | -31.4% | 7,677 | +0.1% | 0.04% | -34.5% |
| Q4 2022 | $892,637 | -28.1% | 7,672 | -23.0% | 0.06% | -38.2% |
| Q3 2022 | $1,242,000 | +84.5% | 9,959 | +26.6% | 0.09% | +81.6% |
| Q2 2022 | $673,000 | +0.6% | 7,866 | +1.1% | 0.05% | -3.9% |
| Q1 2022 | $669,000 | -40.6% | 7,781 | -15.8% | 0.05% | -36.2% |
| Q4 2021 | $1,126,000 | -19.8% | 9,246 | +2.0% | 0.08% | -18.4% |
| Q3 2021 | $1,404,000 | -32.8% | 9,061 | -51.1% | 0.10% | +25.6% |
| Q2 2021 | $2,090,000 | +38.3% | 18,546 | +66.5% | 0.08% | -37.6% |
| Q1 2021 | $1,511,000 | +20.0% | 11,141 | +42.1% | 0.12% | +5.0% |
| Q4 2020 | $1,259,000 | +128.9% | 7,839 | +137.4% | 0.12% | +83.1% |
| Q3 2020 | $550,000 | – | 3,302 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |